Core Viewpoint - Cabbacis has received a new patent for vaporizer pods designed for oral electronic vaporizers, enhancing its intellectual property portfolio in the harm-reduction tobacco product market [1][5]. Group 1: Patent Information - The newly issued U.S. Patent No. 12,527,346 covers vaporizer pods that include blends of reconstituted tobacco and reconstituted hemp, with CBGA as the predominant cannabinoid, and is set to expire on January 1, 2039 [2][3]. - Cabbacis holds three additional U.S. patents related to vaporizer pods containing tobacco and hemp, along with various international patents, strengthening its market position [2][4]. - The patent portfolio comprehensively covers vaporizer pods with blends of conventional-nicotine tobacco and hemp or very-low-nicotine tobacco and hemp across more than 30 countries [5][7]. Group 2: Product Development and Market Position - Cabbacis is focused on commercializing patented harm-reduction tobacco products, including its flagship iBlend™ very-low-nicotine cigarettes and vaporizer pods, which are positioned ahead of proposed FDA regulations to cap nicotine content in U.S. cigarettes [6]. - The company's very-low-nicotine cigarettes have shown high satisfaction ratings in clinical trials and significantly reduced cravings for traditional cigarettes [7]. - Cabbacis has a global patent portfolio consisting of 36 issued patents and various pending applications, primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods, targeting key markets where approximately two-thirds of the world's smokers reside [7].